Project Grant HT9425261E247
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles (UCLA) a $2.076 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of September 1, 2026 through August 31, 2030. The award supports research to define an error-free DNA repair signature as a predictive marker for lethal prostate cancer. This research initiative aligns with the DHA's mission to transform healthcare for military...
- Federal Project Grant Summary The Defense Health Agency awarded a $590,625 Project Grant to the University of California, Los Angeles (UCLA) Office of Research Administration on September 1, 2025, under the Military Medical Research and Development program (CFDA 12.420). The three-year research initiative, concluding August 31, 2028, supports a pilot study investigating dual immunotherapy combining PD-1 and CD73 checkpoint inhibitors with chemotherapy in patients with pancreatic...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $700,000 project grant on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support early detection of ovarian cancer through cell-free DNA (cfDNA) methylome sequencing and protein biomarkers research. The four-year project, concluding May 31, 2030, will be conducted at UCLA's Los Angeles facility through the Office of Research Administration. This award represents DHA's investment...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Beckman Research Institute of the City of Hope a $1.1M project grant effective June 1, 2026 through May 31, 2029 under the Military Medical Research and Development program (CFDA 12.420) to develop LRRC15-targeted Chimeric Antigen Receptor (CAR) T cell therapy for osteosarcoma treatment. This research initiative represents the DHA's investment in innovative cancer immunotherapy solutions with potential military and...
- Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $590,625 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, with a completion date of August 31, 2028. The award funds a pilot study investigating dual immunotherapy combining PD1 (programmed death receptor 1) and CD73 inhibitors in combination with chemotherapy for patients with pancreatic adenocarcinoma, with particular focus on...
- This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
- The University of California, Los Angeles (UCLA), under its Office of Research Administration, received a $157,473 Project Grant award from the Defense Health Agency (DHA) on May 1, 2024 to conduct research for the "TESTING UCHL1 AS A NEW MINIMALLY INVASIVE BIOMARKER AND THERAPEUTIC TARGET FOR NEUROENDOCRINE PROSTATE CANCER" project. This award is funded through the DHA's Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research...
- The University of California, Los Angeles (UCLA) has been awarded a $626,081 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program, administered by the Defense Health Agency. The grant, titled "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance," will support advanced biomedical research to transform healthcare for military service members and the broader public. The research...
- Federal Project Grant Award Summary The Regents of the University of California, San Francisco (UCSF) received a $1.7 million project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on July 1, 2026, with completion scheduled for June 30, 2029. The grant supports research to develop PVRL2 (poliovirus receptor-related 2) as a therapeutic target and biomarker for prostate cancer immunotherapy. This three-year initiative...